Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$76.53 - $131.49
Previous CloseN/A
Volume316.50K
Average Volume (3M)672.82K
Market Cap
$28.32B
Enterprise Value$10.67B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 10, 2025EPS Estimate
0.43Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding237,766,240
10 Day Avg. Volume695,663
30 Day Avg. Volume672,818
Standard Deviation0.22
R-Squared0.00192
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.17
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$141.95Price Target Upside18.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
BioNTech SE News
PremiumCompany Announcements
BioNTech Acquires Biotheus to Strengthen Oncology Strategy
PremiumCompany Announcements
BioNTech Unveils 2025 Strategic Priorities and Pipeline Progress---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessBNTX's PD1/VEGF bispecific BNT327 looks promising in early trials, showing superior efficacy in 6 different cancer settings compared to standard care.
Financial ResourcesBNTX has substantial financial resources to fund aggressive development plans for BNT327, which could be critical for realizing its potential.
Oncology PipelineThe oncology pipeline, particularly the BNT327 product, is seen as having a significant revenue potential, with BNT327 being potentially first to market in key indications.
Bears Say
Financial OutlookManagement expects FY24 revenues to be at the lower end of €2.5-3.1B guidance due to lower net price globally.
Oncology PipelineBNTX's regimen is unlikely to translate to an overall survival benefit compared to the standard of care in PD-L1 CPS>=10 populations.
Vaccine SalesThe overall US COVID vaccine sales estimates for BNTX reflect volumes down approximately 4% year-over-year.
---
Ownership Overview
― Insiders
3.63% Mutual Funds
<0.01% Other Institutional Investors
95.38% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $76.53 and its highest was $131.49 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $28.32B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Mar 10, 2025 which is in 34 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Nov 04, 2024. The company reported $0.839 earnings per share for the quarter, beating the consensus estimate of -$1.59 by $2.429.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $1.534 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is 0.43.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 237,766,240 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of $0.839 in its last earnings report, beating expectations of -$1.59. Following the earnings report the stock price went down -2.252%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in BNTX
---
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$141.95 (18.47% Upside)
$141.95 (18.47% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 77%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 646.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $102.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.45%
12-Months-Change
Fundamentals
Return on Equity
-2.44%
Trailing 12-Months
Asset Growth
6.33%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
---
BNTX Company Deck
---
BNTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, driven by significant revenue growth, advancements in COVID-19 vaccines, and progress within the oncology pipeline. However, there were concerns regarding increased operating costs and contractual disputes. The financial guidance being at the lower end of the range was a noted challenge.Read More>---
BNTX Stock 12 Month Forecast
Average Price Target
$141.95
▲(18.47% Upside)
Technical Analysis
Best Analysts Covering BNTX
1 Year
1 Year Success Rate
9/9 ratings generated profit
1 Year Average Return
+28.96%
reiterated a buy rating 7 days ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.96% per trade.
---